VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viridian Therapeutics Inc (VRDN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential with upcoming catalysts in 2026 and improving financial metrics, the current technical indicators and market sentiment do not present a compelling entry point. The stock is better suited for monitoring until clearer positive signals emerge.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 39.255, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 28.782, indicating potential weakness. Key support levels are at 27.071 and 26.014, while resistance levels are at 30.494 and 31.551.
Strong revenue growth in Q4 2025 (+83.33% YoY) and improving net income (-50.96% YoY). Analysts maintain positive ratings with price targets ranging from $42 to $50.
No recent news or significant trading trends from hedge funds or insiders. The stock has been underperforming in the regular market (-1.90%) and post-market (-0.59%). Congress trading data shows no recent activity, and the stock has a low probability of significant short-term gains.
In Q4 2025, revenue increased by 83.33% YoY to $132,000, and net income improved by 50.96% YoY to -$120.355 million. EPS increased by 28.28% YoY to -1.27. Gross margin remained stable at 100%. While the financials show improvement, the company is still operating at a loss.
Analysts maintain a positive outlook with price targets ranging from $42 to $50. RBC, Jefferies, and Evercore ISI highlight key upcoming catalysts and potential profitability in 2026. UBS initiated coverage with a Buy rating, citing improving biotech fundamentals and upcoming catalysts for Viridian.
